ProCE Banner Activity

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab Combination Therapy in Previously Untreated CLL

Slideset Download
Conference Coverage
Combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and safe as frontline therapy in CLL.

Released: December 09, 2019

Expiration: December 07, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company